Search results
Showing 2751 to 2800 of 2995 results for all
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
This quality standard covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It describes high-quality care in priority areas for improvement. It does not cover areas of national policy, such as the UK Bacillus Calmette-Guérin (BCG) immunisation programme.
View quality statements for QS141Show all sections
Sections for QS141
- Quality statements
- Quality statement 1: Latent tuberculosis testing for people from high-incidence countries
- Quality statement 2: Latent tuberculosis testing for adults with HIV
- Quality statement 3: Rapid diagnosis of pulmonary tuberculosis
- Quality statement 4: Assessment
- Quality statement 5: Directly observed therapy
- Quality statement 6: Accommodation
- Update information
reinforce current best practice because they are based on existing processes that all schools should be following and will become...
NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
View quality statements for QS180Show all sections
Sections for QS180
- Quality statements
- Quality statement 1: Referral – chronic open angle glaucoma and related conditions
- Quality statement 2: Referral for cataract surgery
- Quality statement 3: Treatment – late age-related macular degeneration (wet active)
- Quality statement 4: Monitoring late age-related macular degeneration (wet active)
- Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
- Quality statement 6: Certificate of vision impairment
- Update information
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (TA981)
NICE has withdrawn this guidance. Pfizer has informed the Medicines and Healthcare products Regulatory Agency (MHRA) that the product is being withdrawn. The recall notification is being shared with all healthcare professionals. No new people will start taking voxelotor in the UK. Healthcare professionals should discuss alternative treatment options with people currently having voxelotor.
recognised that individual CBT might not be suitable or meet the needs of all young people with moderate to severe depression and so...
recognised that individual CBT might not be suitable or meet the needs of all young people with moderate to severe depression and so...
knowledge and experience to make the recommendations. The committee agreed that all preterm babies born before 31+0 weeks should receive...
recognised that individual CBT might not be suitable or meet the needs of all young people with moderate to severe depression and so...
Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.
Common mental health problems: identification and pathways to care (CG123)
We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on: Depression in adults Depression in adults with a chronic physical health problem Depression in children and young people Generalised anxiety disorder and panic disorder in adults Obsessive-compulsive disorder and body dysmorphic disorder Social anxiety disorder
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Maternal health: promoting maternal health through community based strategies
Discontinued Reference number: GID-QS10016
Discontinued Reference number: GID-NG10163
Discontinued Reference number: GID-NG10168
Discontinued Reference number: GID-NG10167
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Discontinued Reference number: GID-NG10166
Check our list of appointed suppliers to find out which knowledge resources and services they can offer.
'Trojan horse' treatment recommended for people with multiple myeloma
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.
Evidence-based recommendations on cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for treating intermittent claudication in adults with peripheral arterial disease.
View recommendations for TA223Show all sections
Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care
Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 babies' hearing so far with potential to prevent hearing loss in 200 babies annually.
Sophie Cooper, senior scientific adviser in NICE’s science policy team, explains the importance of the recently published EQ-5D-5L value set and how it has the potential to help us decide if new treatments offer good value for money for the NHS.
Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making
This quality standard covers diagnosing and managing type 1 and type 2 diabetes in children and young people (under 18). It describes high-quality care in priority areas for improvement.
View quality statements for QS125Show all sections
Sections for QS125
- Quality statements
- Quality statement 1: Same-day referral and appointments
- Quality statement 2: Education and information
- Quality statement 3: Intensive insulin therapy and level 3 carbohydrate-counting education for type 1 diabetes
- Quality statement 4: Continuous glucose monitoring in type 1 diabetes
- Quality statement 5: Blood ketone monitoring in type 1 diabetes
- Quality statement 6: Access to mental health professionals with an understanding of type 1 or type 2 diabetes
- Update information
Pregnancy and neonates: newborn blood spot test communication within 6 weeks of birth (IND66)
This indicator covers the proportion of babies with a 'not suspected' result for all the conditions tested for by newborn blood spot testing who have a results letter sent to their parents directly from the child health information service (CHIS) within 6 weeks of birth. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG85
Idelalisib for treating chronic lymphocytic leukaemia (TA359)
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
This guideline covers the diagnosis and management of diverticular disease in people aged 18 years and over. It aims to improve diagnosis and care and help people get timely information and advice, including advice about symptoms and when to seek help.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Evidence-based recommendations on darolutamide (Nubeqa) for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Evidence-based recommendations on benralizumab (Fasenra) for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis in adults.
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development Reference number: GID-TA10886 Expected publication date: TBC
Discontinued Reference number: GID-TA10033
Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued Reference number: GID-TAG507
Discontinued Reference number: GID-TA10133
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued Reference number: GID-TA10164
Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
Discontinued Reference number: GID-TA10711